Results 1 to 10 of about 15,628 (311)

Hepatobiliary disorders associated with TNF-α inhibitors: a pharmacovigilance analysis of FAERS and JADER [PDF]

Frontiers in Immunology
IntroductionTumor necrosis factor-a (TNF-a) inhibitors are widely used for immune-mediated diseases. Their systemic adverse events (AEs) have become increasingly prominent. The hepatobiliary risks of different TNF-a inhibitors were compared in this paper
Hongyu Chen, Shirui Jiang, Jingyu Wang, Ailin Zhang, Liqin Zhu   +4 more
doaj   +2 more sources

Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase [PDF]

Frontiers in Oncology
To evaluate the risk of ocular adverse events (AEs) associated with crizotinib using real-world data from FAERS and VigiBase, and to characterize signal patterns through disproportionality and time-to-onset (TTO) analyses. Reports from FAERS and VigiBase
Shuai Dong, Zhi-chao Jiang, Li Gao, Rong Zhang, Yan Liu   +4 more
doaj   +2 more sources

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]

PLoS ONE, 2015
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Thibault B Ali, Thomas R Schleret, Brian M Reilly, Winston Yuchen Chen, Ruben Abagyan   +4 more
doaj   +6 more sources

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS) [PDF]

Frontiers in Pharmacology
ObjectiveSapropterin dihydrochloride is the first drug for the therapy of phenylketonuria, which is a rare disease that occurs one of 10,000–15,000 newborns.
Jiahong Zhong, Xihui Yu, Zhuomiao Lin
doaj   +2 more sources

Real-world pharmacovigilance study of drug-induced diabetes insipidus from the FAERS database [PDF]

Endocrine Connections
Objective: This study aims to identify potential drugs associated with diabetes insipidus (DI) and track its epidemiological characteristics using the FDA Adverse Event Reporting System (FAERS) database.
Hui Lv, Yue Wu, Lan Lan, Nonger Shen
doaj   +2 more sources

Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD. [PDF]

PLoS ONE
BackgroundSuicide adverse events are a serious concern with zopiclone and eszopiclone. This study assessed the risk of such events by mining data from the FAERS, JADER, and CVARD databases.MethodsThe analysis included reports from Q1 2004 to Q4 2024 for ...
Yinpeng Xu, Fang Li, Mei Zhang, Li Huang
doaj   +2 more sources

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024

Frontiers in Pharmacology
IntroductionIrinotecan is a widely used chemotherapeutic agent for treating colorectal, pancreatic, and ovarian cancers. Despite its therapeutic efficacy, the safety profile of irinotecan necessitates continuous pharmacovigilance due to its association ...
Siyu Lou, Huayou Chen, Zhiwei Cui, Xiyuan Zhang, Chengyu Zhu, Linmei Zhou, Yingyong Ou, Fan Zou   +7 more
doaj   +2 more sources

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

Frontiers in Pharmacology
ObjectiveHypertension is a leading global risk factor for disability and death. Irbesartan, a potent angiotensin II receptor blocker, requires continuous safety monitoring.
Qian Liu, Zhiwei Cui, Chao Deng, Chao Yang, Tao Shi   +4 more
doaj   +2 more sources

Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. [PDF]

PLoS One
Gao Y, Jiang S, Cui Y, Wang Y, Yu L.
europepmc   +2 more sources

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database

Frontiers in Oncology, 2022
BackgroundImmune checkpoint inhibitors (ICIs), the treatment of multiple cancer types, can be associated with respiratory system adverse events (AEs).
Chanjuan Cui, Lei Deng, Wenqing Wang, Xiayang Ren, Yanfeng Wang, Wei Cui   +5 more
doaj   +1 more source